Skip to Content
Merck
CN
All Photos(1)

Documents

Safety Information

C6498

Sigma-Aldrich

Anti-CYP26A1 (481-495) antibody produced in rabbit

IgG fraction of antiserum, buffered aqueous solution

Sign Into View Organizational & Contract Pricing

Synonym(s):
Anti-CP26, Anti-CYP26, Anti-Cytochrome P450, family 26, subfamily A, polypeptide 1 isoform 1, Anti-P450RAI, Anti-P450RAI1
UNSPSC Code:
12352203

biological source

rabbit

conjugate

unconjugated

antibody form

IgG fraction of antiserum

antibody product type

primary antibodies

clone

polyclonal

form

buffered aqueous solution

mol wt

antigen ~56 kDa

species reactivity

human

technique(s)

western blot: 1:500-1:1,000

UniProt accession no.

shipped in

dry ice

storage temp.

−20°C

target post-translational modification

unmodified

Gene Information

human ... CYP26A1(1592)

General description

Cytochrome P450 26A1 is a protein encoded by the CYP26A1 gene in humans. It is mapped on human chromosome 10q23-q24. CYP26A1 gene encodes cytochrome P450 enzyme, specifically involved in metabolic inactivation of retinoic acid (RA).

Immunogen

synthetic peptide corresponding to amino acids 481-495 of human CYP26A1

Application

Yale Center for High Throughput Cell Biology IF-tested antibodies. Each antibody is tested by immunofluorescence against HUVEC cells using the Yale HTCB IF protocol. To learn more about us and Yale Center for High Throughput Cell Biology partnership, visit sigma.com/htcb-if. Anti-CYP26A1 (481-495) antibody produced in rabbit is suitable for western blotting at a dilution of 1:500-1:1,000.

Biochem/physiol Actions

CYP26A1 promotes cell survival properties and contributes to the carcinogenic process. Enhanced CYP26A1 expression causes a functional Vitamin A deficiency (VAD) state in skin that leads to neoplastic transformation of keratinocytes in an early phase during skin carcinogenesis. It has high ligand selectivity but accepts structurally related nuclear receptor agonists as inhibitors. CYP26A1 is the P450 isoform and can be targeted when designing retinoic acid (RA) metabolism blocking agents.

Physical form

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

WGK

nwg

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

常规特殊物品

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Makoto Osanai et al.
Medical molecular morphology, 44(4), 200-206 (2011-12-20)
Vitamin A deficiency (VAD) is associated with increased susceptibility to carcinogenesis. CYP26A1, the gene encoding a cytochrome P450 enzyme specifically involved in metabolic inactivation of retinoic acid (RA), the most active vitamin A derivative, has been shown to result in
Jayne E Thatcher et al.
Biochemical pharmacology, 80(6), 903-912 (2010-06-02)
All-trans retinoic acid (RA) is a critical signaling molecule and its concentration is tightly regulated. Several P450 enzymes including CYP26A1, CYP2C8, and CYP3A4 have been proposed to be responsible for RA clearance in the liver but their quantitative importance has
P450RAI (CYP26A1) maps to human chromosome 10q23-q24 and mouse chromosome 19C2-3.
J A White et al.
Genomics, 48(2), 270-272 (1998-04-02)
Jayne E Thatcher et al.
Molecular pharmacology, 80(2), 228-239 (2011-04-28)
All-trans-retinoic acid (atRA) is the active metabolite of vitamin A. atRA is also used as a drug, and synthetic atRA analogs and inhibitors of retinoic acid (RA) metabolism have been developed. The hepatic clearance of atRA is mediated primarily by
John-Poul Ng-Blichfeldt et al.
Thorax, 72(6), 510-521 (2017-01-15)
Molecular pathways that regulate alveolar development and adult repair represent potential therapeutic targets for emphysema. Signalling via retinoic acid (RA), derived from vitamin A, is required for mammalian alveologenesis, and exogenous RA can induce alveolar regeneration in rodents. Little is

Articles

Phase I biotransformation reactions increase drug compound polarity, mainly occurring in hepatic circulation.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service